This analysis estimated the cost-savings of adding trastuzumab-qyyp for the management of HER2-overexpressing breast and gastric cancer, and gastroesophageal junction (GEJ) adenocarcinoma from French payer and buyer perspectives. Methods: A budget impact model was developed to estimate the cost-savings of trastuzumab-qyyp. Comparators included IV and SC trastuzumab. The French population of 67.19 million was considered for payer perspective and a hypothetical hospital purchasing 10,000 vials of trastuzumab annually was considered for buyer perspective. Costs (drug and administration) and epidemiologic inputs were obtained from public databases. Administration cost was based on the reimbursement provided to hospitals from payer perspective while from buyer perspective it was calculated using healthcare practitioners' wages and time spent. A 76% discount was assumed for trastuzumab-qyyp drug cost relative to IV trastuzumab. Market share was based on a market research study, assuming a 62% conversion of trastuzumab originators to trastuzumab-qyyp. Results: From payer perspective, drug costs decreased by V414,671,781, administration costs increased by V57,030,984 resulting in net cost-savings of V357,640,797 after trastuzumab-qyyp entry. From buyer perspective, drug costs decreased by V101,923,369, administration costs increased by V619,669, resulting in net cost-savings of V101,303,700 after trastuzumab-qyyp entry. Despite the lower administration costs of SC trastuzumab compared to trastuzumab-qyyp, the lower drug costs resulted in net cost-savings. Conclusions: The results demonstrated substantial cost-savings for both payers and buyers after switching patients from trastuzumab originators to trastuzumab-qyyp ® . These costsavings can be used to fund new innovative therapeutics.
synchronization impact on total healthcare cost, three medication adherence improvements from 3 independent studies with different program settings were applied in the model. This model can be customized by entering alternative population sizes, medication synchronization eligible rates, enrollment rates, and cost saving projection year. The primary outcome measure reported net healthcare cost savings per member per year. Results: In a group of 100,000 commercial and Medicaid beneficiaries, if 2.5% enrolled in a medication synchronization program and they improved medication adherence an average of 6.8%, the net healthcare cost savings per member per year is $11.60. If they achieved an 8.4% medication adherence improvement, the net healthcare cost savings per member per year is $14.55; if they achieved a 15.6% medication adherence improvement, the net healthcare cost savings per member per year increases to $27.84. Conclusions: Economic modeling demonstrated that medication synchronization programs can result in substantial healthcare cost savings by improving medication adherence. Proper planning with cost models can help policy makers understand the value of medication synchronization and develop strategies to implement and improve its impact. Legislation, especially state-level, is needed to facilitate programs that help patients synchronize their medications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.